Welcome to our dedicated page for Nexalin Technology news (Ticker: $NXL), a resource for investors and traders seeking the latest updates and insights on Nexalin Technology stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nexalin Technology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nexalin Technology's position in the market.
Rhea-AI Summary
Nexalin Technology, Inc. announced the award of a U.S. patent for its non-invasive, frequency-based deep brain stimulation device, extending IP protection through 2040. The Gen-3 system is a significant advancement to the predecessor Gen-1 system, providing painless brain neural stimulation for mental health conditions. Clinical studies have demonstrated therapeutic benefits in conditions such as treatment-resistant depression, migraines, anxiety, and insomnia, with potential applications in addiction, substance use disorder, Alzheimer’s, traumatic brain injury, and PTSD. The global mental health market was estimated at $383 billion in 2020 and is projected to reach $537 billion by 2030, indicating significant market potential for Nexalin's neurostimulation device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
-
Rhea-AI Summary
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) unveiled its Gen-3 HALO™ Clarity 15 milliamp (mA) neurostimulation device designed to treat a variety of mental health conditions. The device uses Deep Intracranial Frequency Stimulation (DIFS™) to penetrate structures deep in the mid-brain associated with mental health disorders. Clinical trials in China show substantial patient benefit. The device allows treatment at home with remote monitoring by physicians, reducing treatment costs and increasing compliance with standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.69%
Tags
-
Rhea-AI Summary
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) reported positive results of a study on treatment-resistant depression (TRD) using its second-generation neurostimulation device. The study, funded by Wider Come Limited, showed substantial and statistically significant benefits in patients, with no adverse events observed. The company's CEO emphasized the potential impact of the non-invasive, drug-free device on mental healthcare outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
Rhea-AI Summary
Nexalin Technology announces the formation of a Military & Government Advisory Board to support its deep-brain stimulation devices within U.S. government agencies. The Advisory Board will work closely with the company in formulating strategic direction and implementing commercialization. The company welcomes David Lasseter, former Deputy Assistant Secretary of Defense for Policy, as the leader of the Advisory Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.3%
Tags
-
Rhea-AI Summary
Nexalin Technology reports positive results in migraine and depression clinical studies, indicating potential therapeutic benefits of its neurostimulation device. The migraine study showed a significant reduction in pain frequency and degree, with a strong safety profile. The depression study demonstrated better remission and response rates compared to sham treatment. Mental health conditions are increasing globally. The migraine and depression markets are estimated at $3.9 billion and $11.2 billion, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
-
News
Rhea-AI Summary
Nexalin Technology, Inc. announced that its CEO, Mark White, will be participating in a live interview with the 'Big Biz Show' to discuss recent developments and upcoming milestones regarding their non-invasive, frequency-based, deep-brain stimulation medical devices for treating mental health and addiction disorders. The interview will be aired on cable TV, streaming services, and radio in 175 countries, with podcasts available on various platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
Rhea-AI Summary
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) announced the formation of 'Nexalin America' to collaborate with U.S. government agencies for the use of its non-invasive deep-brain stimulation devices in treating PTSD, traumatic brain injury, anxiety, depression, and insomnia. The company has hired industry and government affairs veteran, Ryan Kane, to lead this initiative.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
-
Rhea-AI Summary
Nexalin Technology, Inc. announces that their abstract on traumatic brain injury (TBI) has been accepted for presentation at the 2023 Military Health System Research Symposium. The abstract describes a study using MEG to assess neuronal changes in veterans with combat-related mTBI after treatment with Nexalin's non-invasive deep-brain stimulation device. The reduction of hyperactivity in mTBI suggests the treatment can be effective without side effects. The study builds on prior data in insomnia, which has shown a high correlation with TBI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
-
Rhea-AI Summary
Nexalin Technology has formed a joint venture with Wider Come Limited to develop and distribute its second generation transcranial Alternating Current Stimulation (tACS) devices in China and the Asia Pacific region. Wider will also fund and conduct four clinical trials using Nexalin's devices for the treatment of insomnia, depression, and other indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.21%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.06%
Tags
Nexalin Technology, Inc.
Nasdaq:NXL
NXL Rankings
NXL Stock Data
8.63M
5.89M
22.92%
0.65%
1.28%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
HOUSTON
About NXL
nexalin technology is a non-invasive and drug-free therapy for those living with anxiety, depression and/or insomnia. nexalin’s patented waveform (1 u.s. patent #6904322b2) the nexalin device produces a patented waveform that provides transcranial electrical stimulation (tes). in clinical trials, this unique waveform resulted in the greatest increase in beta-endorphins. the nexalin device has undergone extensive safety analysis with the results clearly indicating that the device is safe for its intended use. additionally, the fda classification of the device for clinical trials places it into a non-significant risk (low risk device) category. natural frequency will promote balance in the brain by normalizing neurochemistry.this effectiveness of this unique therapy is long lasting and fda approved. laboratory and clinical evidence suggest that nexalin’s patented electrical stimulation affects the hypothalamus and related brain structures to adapt and change the levels of neurochemicals